Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.

Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72

Cancer genome landscapes. Science (2013) 25.33

The DNA-damage response in human biology and disease. Nature (2009) 17.86

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest (2011) 14.22

Pancreatic cancer. Lancet (2004) 11.63

Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer (2009) 11.25

Principles of cancer therapy: oncogene and non-oncogene addiction. Cell (2009) 10.96

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol (2009) 9.18

53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell (2010) 8.70

Translating cancer research into targeted therapeutics. Nature (2010) 7.33

Cancer drug resistance: an evolving paradigm. Nat Rev Cancer (2013) 6.77

PARP inhibition: PARP1 and beyond. Nat Rev Cancer (2010) 6.70

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature (2008) 5.98

Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci U S A (2010) 5.60

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med (2015) 5.39

The DNA damage response and cancer therapy. Nature (2012) 5.25

Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer (2009) 5.12

The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol Cell (2010) 5.06

How the fanconi anemia pathway guards the genome. Annu Rev Genet (2009) 4.94

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med (2009) 4.68

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A (2008) 4.61

Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11. Cell (2011) 4.41

Translating insights from the cancer genome into clinical practice. Nature (2008) 4.37

PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. Nucleic Acids Res (2006) 4.06

Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A (2011) 3.99

Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol (2010) 3.98

A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet (2010) 3.86

BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol (2012) 3.86

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res (2012) 3.74

Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci U S A (2007) 3.58

Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol (2010) 3.54

Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell (2011) 3.53

A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science (2011) 3.49

Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer (2009) 3.46

New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nat Rev Mol Cell Biol (2012) 3.45

BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res (2006) 3.29

ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov (2011) 3.27

miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell (2010) 3.27

Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet (2011) 3.25

Evolution of the cancer genome. Nat Rev Genet (2012) 3.24

Acetylation limits 53BP1 association with damaged chromatin to promote homologous recombination. Nat Struct Mol Biol (2013) 3.18

A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. Nat Struct Mol Biol (2011) 3.10

RIF1 is essential for 53BP1-dependent nonhomologous end joining and suppression of DNA double-strand break resection. Mol Cell (2013) 3.05

PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination. EMBO J (2009) 2.99

A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J (2008) 2.95

PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov (2012) 2.89

On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1. Genes Dev (2012) 2.82

Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell (2013) 2.81

Susceptibility pathways in Fanconi's anemia and breast cancer. N Engl J Med (2010) 2.79

Human SIRT6 promotes DNA end resection through CtIP deacetylation. Science (2010) 2.74

DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer (2012) 2.70

Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment. Cancer Res (2010) 2.68

Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res (2011) 2.64

Inhibition of homologous recombination by the PCNA-interacting protein PARI. Mol Cell (2011) 2.61

Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer (2009) 2.60

Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors. Nat Biotechnol (2012) 2.58

Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res (2008) 2.56

Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov (2012) 2.53

Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci U S A (2008) 2.53

Balancing repair and tolerance of DNA damage caused by alkylating agents. Nat Rev Cancer (2012) 2.52

The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol (2011) 2.52

Essential gene profiles in breast, pancreatic, and ovarian cancer cells. Cancer Discov (2011) 2.49

Regulation of multiple DNA repair pathways by the Fanconi anemia protein SLX4. Blood (2012) 2.48

Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci U S A (2011) 2.47

Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer (2008) 2.47

Functional viability profiles of breast cancer. Cancer Discov (2011) 2.44

Homologous recombination and its regulation. Nucleic Acids Res (2012) 2.44

Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin Oncol (2010) 2.43

Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nat Struct Mol Biol (2011) 2.42

Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci U S A (2007) 2.39

Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol (2012) 2.39

Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nat Med (2011) 2.35

Next-generation sequencing for cancer diagnostics: a practical perspective. Clin Biochem Rev (2011) 2.31

A decade of systems biology. Annu Rev Cell Dev Biol (2010) 2.30

Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res (2008) 2.29

Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. Nat Genet (2016) 2.28

Methylating agents and DNA repair responses: Methylated bases and sources of strand breaks. Chem Res Toxicol (2006) 2.25

Regulation of DNA-damage responses and cell-cycle progression by the chromatin remodelling factor CHD4. EMBO J (2010) 2.25

Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors. Science (2015) 2.24

Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol (2013) 2.24

Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. Breast Cancer Res Treat (2011) 2.23

Synergistic inhibition of hepatocellular carcinoma growth by cotargeting chromatin modifying enzymes and poly (ADP-ribose) polymerases. Hepatology (2012) 2.23

BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair. Mol Cell (2012) 2.21

The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat Rev Cancer (2012) 2.20

Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res (2011) 2.19

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol (2014) 2.18

Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers. Clin Cancer Res (2010) 2.12

MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool. Nature (2014) 2.11

The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice. Cancer Prev Res (Phila) (2014) 2.10

Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res (2011) 2.08

Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination. Nat Struct Mol Biol (2010) 2.07

Targeting ATR and Chk1 kinases for cancer treatment: a new model for new (and old) drugs. Mol Oncol (2011) 2.07

PALB2/FANCN: recombining cancer and Fanconi anemia. Cancer Res (2010) 2.07

RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis. Nat Rev Cancer (2011) 2.06

The zinc-finger domains of PARP1 cooperate to recognize DNA strand breaks. Nat Struct Mol Biol (2012) 2.05

53BP1 mediates productive and mutagenic DNA repair through distinct phosphoprotein interactions. Cell (2013) 2.05

Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair. Nature (2015) 2.04

HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proc Natl Acad Sci U S A (2007) 2.03

Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat Rev Clin Oncol (2011) 2.02

Evolutionary pathways in BRCA1-associated breast tumors. Cancer Discov (2012) 2.01

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 24.75

Signatures of mutational processes in human cancer. Nature (2013) 21.63

A DNA damage checkpoint response in telomere-initiated senescence. Nature (2003) 12.55

Human CtIP promotes DNA end resection. Nature (2007) 10.63

Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer (2004) 10.31

Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res (2004) 9.70

MDC1 directly binds phosphorylated histone H2AX to regulate cellular responses to DNA double-strand breaks. Cell (2005) 8.39

ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nat Cell Biol (2005) 8.27

Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24

Orchestration of the DNA-damage response by the RNF8 ubiquitin ligase. Science (2007) 7.61

Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage. Nature (2005) 7.45

Translating cancer research into targeted therapeutics. Nature (2010) 7.33

Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol (2010) 6.88

The Mre11 complex: at the crossroads of dna repair and checkpoint signalling. Nat Rev Mol Cell Biol (2002) 6.44

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol (2010) 6.42

Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res (2006) 6.28

CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature (2003) 6.00

Resistance to therapy caused by intragenic deletion in BRCA2. Nature (2008) 5.85

XLF interacts with the XRCC4-DNA ligase IV complex to promote DNA nonhomologous end-joining. Cell (2006) 5.62

Dynamics of DNA damage response proteins at DNA breaks: a focus on protein modifications. Genes Dev (2011) 5.60

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med (2015) 5.39

Interfaces between the detection, signaling, and repair of DNA damage. Science (2002) 5.33

A pathway of double-strand break rejoining dependent upon ATM, Artemis, and proteins locating to gamma-H2AX foci. Mol Cell (2004) 5.29

The DNA damage response and cancer therapy. Nature (2012) 5.25

DNA helicases Sgs1 and BLM promote DNA double-strand break resection. Genes Dev (2008) 5.07

CD24 staining of mouse mammary gland cells defines luminal epithelial, myoepithelial/basal and non-epithelial cells. Breast Cancer Res (2005) 4.79

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med (2009) 4.68

BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell (2010) 4.66

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A (2008) 4.61

MDC1 is required for the intra-S-phase DNA damage checkpoint. Nature (2003) 4.56

AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res (2009) 4.50

gammaH2AX and MDC1: anchoring the DNA-damage-response machinery to broken chromosomes. DNA Repair (Amst) (2006) 4.36

Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35

Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction. EMBO J (2005) 4.31

Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks. Nature (2009) 4.30

Binding of chromatin-modifying activities to phosphorylated histone H2A at DNA damage sites. Mol Cell (2004) 4.17

Yeast Rtt109 promotes genome stability by acetylating histone H3 on lysine 56. Science (2007) 4.07

CDK targets Sae2 to control DNA-end resection and homologous recombination. Nature (2008) 3.96

FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res (2010) 3.89

Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81

Poly(ADP-ribose)-dependent regulation of DNA repair by the chromatin remodeling enzyme ALC1. Science (2009) 3.68

Stem cells and breast cancer: A field in transit. Nat Rev Cancer (2003) 3.47

Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining. Nat Struct Mol Biol (2010) 3.27

Human CtIP mediates cell cycle control of DNA end resection and double strand break repair. J Biol Chem (2009) 3.24

Dissociation of estrogen receptor expression and in vivo stem cell activity in the mammary gland. J Cell Biol (2006) 3.24

Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet (2012) 3.20

Mdc1 couples DNA double-strand break recognition by Nbs1 with its H2AX-dependent chromatin retention. EMBO J (2004) 3.20

hnRNP K: an HDM2 target and transcriptional coactivator of p53 in response to DNA damage. Cell (2005) 3.18

A means to a DNA end: the many roles of Ku. Nat Rev Mol Cell Biol (2004) 3.07

Novel breast cancer susceptibility locus at 9q31.2: results of a genome-wide association study. J Natl Cancer Inst (2011) 3.05

The FHA domain. FEBS Lett (2002) 3.03

Screen for DNA-damage-responsive histone modifications identifies H3K9Ac and H3K56Ac in human cells. EMBO J (2009) 2.98

A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J (2008) 2.95

4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem (2008) 2.89

Distinct roles of chromatin-associated proteins MDC1 and 53BP1 in mammalian double-strand break repair. Mol Cell (2007) 2.88

PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A (2010) 2.79

Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov (2012) 2.74

Human SIRT6 promotes DNA end resection through CtIP deacetylation. Science (2010) 2.74

The interaction of Alba, a conserved archaeal chromatin protein, with Sir2 and its regulation by acetylation. Science (2002) 2.69

Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature (2012) 2.66

Suppression of HIV-1 infection by a small molecule inhibitor of the ATM kinase. Nat Cell Biol (2005) 2.63

Functional and molecular characterisation of mammary side population cells. Breast Cancer Res (2002) 2.63

Genetic interactions in cancer progression and treatment. Cell (2011) 2.54

Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1. Cancer Discov (2012) 2.53

Proteomic investigations reveal a role for RNA processing factor THRAP3 in the DNA damage response. Mol Cell (2012) 2.51

Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1. Cancer Res (2003) 2.49

Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer Res (2006) 2.45

Functional viability profiles of breast cancer. Cancer Discov (2011) 2.44

Utilizing RNA interference to enhance cancer drug discovery. Nat Rev Drug Discov (2007) 2.43

Small-molecule-induced DNA damage identifies alternative DNA structures in human genes. Nat Chem Biol (2012) 2.41

Analysis of PALB2/FANCN-associated breast cancer families. Proc Natl Acad Sci U S A (2007) 2.41

Targeted therapy for cancer using PARP inhibitors. Curr Opin Pharmacol (2008) 2.40

Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. Blood (2012) 2.38

A distinct spectrum of copy number aberrations in pediatric high-grade gliomas. Clin Cancer Res (2010) 2.37

MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53. Cancer Cell (2009) 2.36

Phospho-dependent interactions between NBS1 and MDC1 mediate chromatin retention of the MRN complex at sites of DNA damage. EMBO Rep (2008) 2.35

Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries. Bioorg Med Chem Lett (2004) 2.35

A heterotrimeric PCNA in the hyperthermophilic archaeon Sulfolobus solfataricus. Mol Cell (2003) 2.34

DNA damage signaling in response to double-strand breaks during mitosis. J Cell Biol (2010) 2.30

Suppression of homologous recombination by the Saccharomyces cerevisiae linker histone. Mol Cell (2003) 2.30

Functional links between telomeres and proteins of the DNA-damage response. Genes Dev (2004) 2.29